Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
RESEARCH TOOLSreports
Holding TLSI?
Track your performance easily
TLSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.50 - $10.42
Previous CloseN/A
Volume4.84K
Average Volume (3M)48.73K
Market Cap
$145.76M
Enterprise Value$134.33M
Total Cash (Recent Filing)$1.33M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Apr 07, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding30,493,137
10 Day Avg. Volume38,983
30 Day Avg. Volume48,734
Standard Deviation0.19
R-Squared0.02
Alpha-0.00825
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.84
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit8.45
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$11.92Price Target Upside149.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
TriSalus Life Sciences News
PremiumCompany Announcements
TriSalus Announces Leadership Changes and New Incentive Program
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Standard Of CareTriSalus's TriNav catheter significantly improves drug delivery with Pressure Enabled Drug Delivery (PEDD), which is on its way to becoming the standard of care for delivering therapeutics to tumors in the liver.
Product Launch And Market ExpansionThe launch of the TriNav LV Infusion System and TriGuide Guiding Catheter expands its addressable liver market.
Revenue Growth And Market ShareRevenue was up 42% year-over-year due to both activation of new accounts and deeper penetration within existing ones.
Bears Say
Clinical TrialsNelitolimod in combination with immune checkpoint inhibitors did not show improvements in the treatment of liver metastases from uveal melanoma.
Financial PerformanceThe risk-adjusted revenues ascribed to nelitolimod decreased to $449M (previously $746M) and royalty revenue decreased to $36M (previously $56M) by FY34.
Strategic PrioritizationTriSalus to deprioritize nelitolimod in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
---
Options Prices
Currently, No data available
---
Ownership Overview
44.09% Insiders
1.80% Mutual Funds
4.23% Other Institutional Investors
48.53% Public Companies and Individual Investors
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.50 and its highest was $10.42 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $145.76M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Apr 07, 2025 which is in 87 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Nov 14, 2024. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.347 by $0.227.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.31.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 30,493,137 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.347. Following the earnings report the stock price went down -10.889%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Among the largest hedge funds holding TriSalus Life Sciences’s share is Duquesne Family Office LLC. It holds TriSalus Life Sciences’s shares valued at 2M.
---
TriSalus Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.92 (149.37% Upside)
$11.92 (149.37% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 179.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $207.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.5%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.11%
Trailing 12-Months
Company Description
TriSalus Life Sciences
MedTech Acquisition Corp is a blank check company.
---
TLSI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
TriSalus Life Sciences shows strong revenue growth and operational improvements with significant product launches and market opportunities. However, the company faces challenges with cash flow management and dependency on future partnerships for further advancements.Read More>---
TLSI Stock 12 Month Forecast
Average Price Target
$11.92
▲(149.37% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Atara Biotherapeutics
―
Blueprint Medicines
―
Arcturus Therapeutics
―
Best Analysts Covering TLSI
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-14.55%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -14.55% per trade.
---